Skip to main content
. 2015 Oct 12;6(35):38079–38092. doi: 10.18632/oncotarget.5752

Figure 6. Reduced DNA damage and/or bcl-2 up-regulation by hTERT over-expression in bortezomib-treated cells.

Figure 6

A. and B. Reduced 53BP1 foci by hTERT over-expression. Immuno-fluorescence analyses were performed to detect the presence of 53BP1 foci in both control and hTERT-over-expressed cells treated with bortezomib and percentages of positive cells calculated. (A) HEL-control and HEL-hTERT cells. Top panels: representative of 53BP1 foci in HEL cells and their hTERT-over-expressed counterparts with and without bortezomib. Bottom panel: 53BP1 foci-positive cells in each group based on 4 independent experiments. (B) BGC-823-control and BGC-823-hTERT cells. * and **: P < 0.05 and 0.01, respectively. C. Bcl-2 up-regulation in HEL-hTERT cells. Left panel: Immunoblotting was performed to analyze bcl2 protein expression. Changes in folds were based on the bcl2 signal densities. Right panel: bcl2 expression levels in HEL-control and hTERT cells from four independent experiments. D. Bcl2 down-regulation and caspase 3 activation in bortezomib-treated HEL cells. Control and hTERT-over-expressed HEL cells were treated with bortezomib for 24 hours and then analyzed for bcl-2 expression and caspase 3 cleavage using Western blot. Bcl2 levels were calculated based on the scanned bcl2 signal densities in the image. Shown is representative of three independent experiments. BTZ, bortezomib.